ASX News

First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer

Melbourne (Australia) – 5 August 2021. Telix announces the first patient has been dosed in its ‘CUPID’ Phase I study of TLX592 in patients with advanced prostate cancer.

 

Telix is pleased to announce today that the first patient has been dosed in its ‘CUPID’ first-in-human Phase I study of the Company’s next generation prostate cancer therapy candidate TLX592 in patients with advanced prostate cancer.

The objective of the CUPID (64Cu PSMA Imaging and (Bio)Distribution) study is to evaluate the safety, tolerability, pharmacokinetics, biodistribution and radiation dosimetry of TLX592. This investigational agent will become Telix’s first targeted alpha therapy (“TAT”) for the treatment of patients with advanced prostate cancer. The CUPID study, which is being conducted in collaboration with GenesisCare, will recruit up to 15 patients and will initially use copper-64 (64Cu) to evaluate biodistribution and dosing, before proceeding to studies with actinium-225 (225Ac) TAT.

TLX592 targets prostate specific membrane antigen (PSMA), as does the Company’s existing TLX591 (177Lu-rosapatamab) prostate cancer therapy program. However, TLX592 has been engineered with Telix’s proprietary RADmAb® antibody technology to clear far more rapidly from a patient’s circulation than unmodified antibodies, while maintaining TLX591’s specificity for tumour-expressed PSMA and hepatic (liver) clearance, rendering it potentially more suitable for use as a targeting agent for 225Ac, a potent therapeutic alpha emitting radionuclide.

Principal Investigator for the CUPID study and GenesisCare Group Clinical Director (Theranostics) Clinical Professor Nat Lenzo stated, “The initiation of the Phase I CUPID PET imaging study represents a significant milestone in the development of next generation alpha particle treatments, a promising new frontier in nuclear medicine, with the potential to significantly improve outcomes for patients. The very high energy, short range properties of targeted alpha therapy have the potential to offer a potent and highly selective anti-cancer therapy to patients with advanced prostate cancer.”

Founder and Chief Executive Officer of GenesisCare, Dan Collins, said: “As one of the largest global providers of integrated cancer care, GenesisCare is uniquely positioned to partner with leading research institutions and pharmaceutical companies on bold new solutions to bring patients world-class cancer care, closer to home. We are proud to partner with Telix Pharmaceuticals on the CUPID trial which may bring new hope to thousands of men living with prostate cancer in Australia and around the globe.”  

Telix CEO, Dr. Christian Behrenbruch added, “One of Telix’s key objectives is to establish category leadership in urologic oncology, thereby being able to offer patients with prostate cancer a broad suite of state-of-the-art diagnostic imaging and therapeutic options. With this objective in mind, TLX592 represents Telix’s most significant proprietary antibody development to date. It is our aim to develop this program for both the early stages of metastatic prostate cancer, as well as for later stage patients no longer responding to lutetium therapy, in tandem with the 177Lu-based TLX591. We wish to express our gratitude to Professor Nat Lenzo and his clinical collaborators, as well as the patients who have made this important milestone possible.”

To read the full ASX disclosure please click here.

To return to Telix’s homepage please click here.

More Articles

Corporate Spotlight

Second Industry Body Updates Guidance for Use of PSMA PET Imaging

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 21 September 2021. Telix welcomes SNMMI updated Appropriate Use Criteria for PSMA PET...

Corporate Spotlight

Telix at AdMeTech Summit on Precision Diagnosis and Treatment of Prostate Cancer

16 September 2021 – Clinical Spotlight | Telix to support and participate in AdMeTech 5th Global Summit on Precision Diagnosis...

ASX News

NCCN Guidelines Updated to Include PSMA-PET Imaging

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 14 September 2021. Telix welcomes the updated NCCN Guidelines® for prostate cancer, which includes...

ASX News

FDA Approves Phase II Kidney Cancer Therapy Study

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 14 September 2021. Telix announces the FDA has accepted the IND Application to...

ASX News

Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging

Melbourne (Australia) and Bologna (Italy) – 13 September 2021. Telix enters a commercial distribution agreement with Radius for Telix’s prostate...

ASX News

Japanese Prostate Cancer Imaging Study Completes Enrolment

Melbourne (Australia) and Kyoto (Japan) – 9 September 2021. Telix has completed a Phase I clinical trial of TLX591-CDx for...

ASX News

Telix to Collaborate with Kettering Health on Diagnostic PSMA Imaging & Targeting Theranostics

Melbourne (Australia), Indianapolis (IN, U.S.A.), and Kettering (OH, U.S.A.) – 7 September 2021. Telix announces collaboration with Kettering Health on...

ASX News

Telix and Lightpoint Medical to Collaborate on Radioguided Surgery

Melbourne (Australia) – 23 August 2021. Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI®...

ASX News

Telix Half-Year Results 2021 and Company Update Conference Call

Melbourne (Australia) – 19 August 2021. Telix announces Half-Year Results 2021 and provides shareholder update

ASX News

Telix Expands Prostate Cancer Activity with GenesisCare Collaboration

Melbourne (Australia) – 19 August 2021. Telix releases details of two ancillary studies under the ProstACT program, including a Phase...

ASX News

Telix and Merck to Commence Pan-Cancer Clinical Combination Studies

Melbourne (Australia) – 18 August 2021. Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany.

ASX News

Two New Studies to Explore Telix Assets in Breast Cancer Theranostics

Melbourne (Australia) – 18 August 2021. Telix announces two new studies to evaluate the potential utility of TLX591-CDx and TLX250-CDx...

ASX News

Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®

Melbourne and Adelaide (Australia) – 17 August 2021. Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being...

ASX News

Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia

Melbourne (Australia) and London (United Kingdom) – 17 August 2021. Telix announces Phase II academic study of TLX66 in children...

ASX News

Telix H1 2021 Results and Company Update Conference Call

Melbourne (Australia) – 11 August 2021. Telix to hold investor conference call to present H1 2021 financial results and Company...

ASX News

First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer

Melbourne (Australia) – 5 August 2021. Telix announces the first patient has been dosed in its ‘CUPID’ Phase I study...

Corporate Spotlight

Ms. Helen Hovenga Joins Telix as Chief People Officer

4 August 2021 – Corporate Spotlight | Telix announces the appointment of Ms. Helen Hovenga in the role of Chief...

ASX News

Telix Seneffe Production Facility: Progress Update

Melbourne (Australia) and Seneffe (Belgium) – 30 July 2021. Telix authorised to decommission first of two cyclotrons at Seneffe radiopharmaceutical...

ASX News

Activities Report and Appendix 4C for June 2021 Quarter

Melbourne (Australia) – 22 July 2021. Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 June...

ASX News

ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update

Melbourne (Australia) – 20 July 2021. Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer...

Corporate Spotlight

Telix Appoints Gabrielle Wermenbol as Chief Financial Officer, EMEA

19 July 2021 – Corporate Spotlight | Gabrielle Wermenbol joins Telix as Chief Financial Officer, Europe, Middle East & Africa...

Corporate Spotlight

Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations

Melbourne (Australia) – 12 July 2021. Telix announces that Ms. Kyahn Williamson has joined the Telix executive leadership team in...

ASX News

First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer

Melbourne (Australia) – 23 June 2021. Telix announces that a first patient has been dosed in a Phase I study...

ASX News

IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update

Melbourne (Australia) – 21 June 2021. Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on...

ASX News

Telix Update on FDA New Drug Application Review for Illuccix®

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 17 June 2021. Telix announces participation in a late-cycle meeting with the U.S....

Corporate Spotlight

Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research

MELBOURNE, Australia and INDIANAPOLIS 14 June, 2021 – Telix announces the launch of a new educational platform focused on radiopharmaceutical...

Corporate Spotlight

Telix launches “Gallium Wave” Awareness Website

Melbourne (Australia) and Indianapolis (U.S.A.) – 11 June 2021. Telix announces the launch of a new website “Gallium Wave”, as...

Corporate Spotlight

Scott Law joins Telix as SVP Global Manufacturing Operations

11 June 2021 – Corporate Spotlight | Scott Law joins Telix as Senior Vice President Global Manufacturing Operations

ASX News

Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy

Liège (Belgium) and Gothenburg (Sweden) – 7 June 2021. Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of...